Janux Therapeutics, Inc.

JANX Healthcare Biotechnology

Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.

Revenue
0.00%
EPS
+12.8%
Free cash flow
−94.5%

Quarter to September 2026, against a year earlier

17.63 1.57 +9.78%
Market cap
$981.9M
P/E
0.0×
Fwd P/E
−10.1×
Dividend yield
—
F-score
2/9
Altman Z
11.61
Beneish M
n/a
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 5 Nov
Piotroski F-Score

+8 more TTM periods

— — — 4
ROE
(11.48%) (11.72%) (10.70%) (10.58%)
ROA
(11.02%) (11.01%) (10.06%) (9.94%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(11.90%) (12.09%) (11.07%) (11.00%)
Average Days of Receivables
— 901.43 2.27 4.51
Free Cash Flow per Share
(1.34) (1.25) (0.67) (0.86)
Free Cash Flow
(83.28) (78.49) (41.92) (54.16)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026